Stroke Models for Preclinical Trials of Neuroprotective Agents
With advances in the understanding of the pathophysiology of ischemic brain injury, several therapeutic regimens have been conceived to protect the brain during or following ischemic insult. Despite the numerous claims of therapeutic success in animal models in the past two decades, no therapeutic agents have been approved by the Food and Drug Administration (FDA) for patients with acute ischemic stroke in the United States (Pulsinelli and Buchan, 1989). Lack of success in extrapolating therapeutic efficacy in animal models to stroke patients has raised concern about the validity of using animal stroke models to develop therapeutic regimens (Wiebers et al., 1990). Several recent editorials have extensively discussed the pros and cons of animal stroke models (Graham, 1988; Molinari, 1988; Wiebers et al., 1990; Zivin and Grotta, 1990). An important issue, i.e., the quality of animal trials, however, has not been adequately addressed previously and will be the main focus of this review.
KeywordsMiddle Cerebral Artery Infarct Size Ischemic Insult Neuroprotective Agent Ischemic Brain Injury
Unable to display preview. Download preview PDF.
- Boxer PA, Cordon JJ, Mann ME, Rodolosi LC, Vartanian MG. Rock DM, Talor CP, Marcoux FW (1990): Comparison of phenytoin with noncompetitive Nmethyl-D-aspartate antagonists in a model of focal brain ischemia in rat. Stroke 21: III 47–51Google Scholar
- Buchan A, Pulsinelli WA (1990): Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. Neuroscience 10 (1): 311–316Google Scholar
- Hsu CY, Norris JW, Hogan EL, Bladin P, Dinsdale HB, Yatsu FM, Earnest MP, Scheinberg P, Caplan LR, Karp HR, Swanson PD, Feldman RG, Cohen MM, Mayman CI, Cobert B, Savitsky JP for Pentoxifylline Study Group (1988): Pentoxifylline in acute nonhemorrhagic stroke: A randomized, placebo-controlled double-blind trial. Stroke 19: 716–722CrossRefGoogle Scholar
- Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY (1989): Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 256: H589–H593Google Scholar
- Molinari GF (1986): Experimental models of ischemic stroke. In: Stroke, Pathophysiology, Diagnosis, and Management, Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. New York: Churchill Livingstone, pp 57–73Google Scholar
- Nakayama H., Ginsberg MD, Dietrich WD (1988): s-Emopamil, a novel calcium channel blocker and serotonin SZ antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat. Neurology 38: 1667–1673Google Scholar
- Pulsinelli WA, Buchan A (1989): The utility of animal ischemia models in predicting pharmacotherapeutic response in the clinical setting. In: Cerebrovascular Diseases, Ginsberg MD, Dietrich WD, eds. New York: Raven Press, pp 87–91Google Scholar
- Reimer KA, Jennings RB, Cobb FR, Murdock RH, Greenfield Jr JC, Becker LC, Bulkley BH, Hutchins GM, Schwartz Jr RP, Bailey KR, Passamani ER (1985): Animal models for protecting ischemic myocardium: Results of the NHLBI Cooperative Study. Circ Res 56: 651–665Google Scholar
- Schallert T, Jones TA, Linder MD (1990): Multilevel transneuronal degeneration after brain damage: Behavioral events and effects of anticonvulsant -y-aminobutyric acid-related drugs. Stroke 21: III 143–146Google Scholar
- Volpe BT, Davis HP (1989): An approach to the functional analysis of an animal model of ischemic injury. In: Cerebrovascular Diseases, Ginsberg MD, Dietrich WD, eds. New York: Raven Press, pp 335–340Google Scholar